Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bioartificial liver developer Vital Therapies nets $57.8mm in IPO

Executive Summary

Vital Therapies Inc. (VTI), which is attempting to commercialize a bioartificial liver, netted $57.8mm in its IPO of 5.2mm shares (including the overallotment) at $12, below its $13-15 price range. Some directors, officers, and existing investors are buying $30mm of the IPO shares. The company first filed in October 2013 and then postponed a month later because of poor market conditions. Last month VTI said it would try for the IPO again.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Medical Devices
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies

Advertisement
UsernamePublicRestriction

Register